Literature DB >> 11607947

Discontinuation of lithium augmentation in an elderly cohort.

S Fahy1, B A Lawlor.   

Abstract

OBJECTIVES: To observe the effects of gradual discontinuation of lithium augmentation therapy in a group of patients over the age of 65 years and to measure the rate of relapse and to identify any factors which would predict relapse.
METHODS: This was a naturalistic study involving 21 patients who were on lithium augmentation and whose lithium was discontinued for a variety of clinical reasons. In most cases lithium was tapered and discontinued over a period of 2-12 weeks. Demographic and other variables were collected at baseline and compared between those who remained well and those that subsequently relapsed.
RESULTS: Eleven patients (52.4%) relapsed following discontinuation of lithium augmentation. Those who relapsed had been on lithium for significantly longer than those who remained well off lithium (p = 0.007). There was a trend towards more hospital admissions in the relapse group (p = 0.062).
CONCLUSIONS: When lithium augmentation therapy is discontinued in elderly depressives over half of these patients relapse. A longer duration of prediscontinuation lithium treatment and more hospital admissions appear to be associated with increased risk of relapse. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11607947     DOI: 10.1002/gps.453

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  10 in total

1.  Acute renal and neurotoxicity in older lithium users: How can we manage and prevent these events in patients with late-life mood disorders?

Authors:  Vincent Laliberté; Ching Yu; Soham Rej
Journal:  J Psychiatry Neurosci       Date:  2015-07       Impact factor: 6.186

Review 2.  Lithium dosing and serum concentrations across the age spectrum: from early adulthood to the tenth decade of life.

Authors:  Soham Rej; Serge Beaulieu; Marilyn Segal; Nancy C P Low; Istvan Mucsi; Christina Holcroft; Kenneth Shulman; Karl J Looper
Journal:  Drugs Aging       Date:  2014-12       Impact factor: 3.923

Review 3.  Chronic kidney disease in lithium-treated older adults: a review of epidemiology, mechanisms, and implications for the treatment of late-life mood disorders.

Authors:  Soham Rej; Dominique Elie; Istvan Mucsi; Karl J Looper; Marilyn Segal
Journal:  Drugs Aging       Date:  2015-01       Impact factor: 3.923

Review 4.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

5.  The effect of serum lithium levels on renal function in geriatric outpatients: a retrospective longitudinal study.

Authors:  Soham Rej; Karl Looper; Marilyn Segal
Journal:  Drugs Aging       Date:  2013-06       Impact factor: 3.923

6.  The McGill Geriatric Lithium-Induced Diabetes Insipidus Clinical Study (McGLIDICS).

Authors:  Soham Rej; Marilyn Segal; Nancy C P Low; Istvan Mucsi; Christina Holcroft; Kenneth Shulman; Karl Looper
Journal:  Can J Psychiatry       Date:  2014-06       Impact factor: 4.356

Review 7.  Role of lithium augmentation in the management of major depressive disorder.

Authors:  Michael Bauer; Mazda Adli; Roland Ricken; Emanuel Severus; Maximilian Pilhatsch
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

Review 8.  Going beyond antidepressant monotherapy for incomplete response in nonpsychotic late-life depression: a critical review.

Authors:  Donovan T Maust; David W Oslin; Michael E Thase
Journal:  Am J Geriatr Psychiatry       Date:  2013-02-06       Impact factor: 4.105

Review 9.  The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis.

Authors:  Amy T Page; Rhonda M Clifford; Kathleen Potter; Darren Schwartz; Christopher D Etherton-Beer
Journal:  Br J Clin Pharmacol       Date:  2016-06-13       Impact factor: 4.335

10.  Atorvastatin lowers serum calcium levels in lithium-users: results from a randomized controlled trial.

Authors:  Jocelyn Fotso Soh; Katie Bodenstein; Harmehr Sekhon; Soham Rej; Oriana Hoi Yun Yu; Outi Linnaranta; Suzane Renaud; Artin Mahdanian; Chien-Lin Su; Istvan Mucsi; Benoit Mulsant; Nathan Herrmann; Tarek Rajji; Serge Beaulieu
Journal:  BMC Endocr Disord       Date:  2022-09-24       Impact factor: 3.263

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.